Pfizer Inc (PFE)vsSandisk Corp (SNDK)
PFE
Pfizer Inc
$26.30
+0.57%
HEALTHCARE · Cap: $149.77B
SNDK
Sandisk Corp
$1,096.51
+3.04%
TECHNOLOGY · Cap: $161.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 375% more annual revenue ($62.58B vs $13.18B). SNDK leads profitability with a 34.2% profit margin vs 12.4%. PFE trades at a lower P/E of 19.4x. SNDK earns a higher WallStSmart Score of 69/100 (B-).
PFE
Hold49
out of 100
Grade: D+
SNDK
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.7%
Fair Value
$37.12
Current Price
$26.30
$10.82 discount
Margin of Safety
-52.4%
Fair Value
$413.56
Current Price
$1096.51
$682.95 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Every $100 of equity generates 39 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 70.0%
Revenue surging 251.0% year-over-year
Earnings expanding 618.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Premium valuation, high expectations priced in
Trading at 15.9x book value
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bull Case : SNDK
The strongest argument for SNDK centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 34.2% and operating margin at 70.0%. Revenue growth of 251.0% demonstrates continued momentum.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : SNDK
The primary concerns for SNDK are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
PFE profiles as a declining stock while SNDK is a growth play — different risk/reward profiles.
SNDK is growing revenue faster at 251.0% — sustainability is the question.
PFE generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SNDK scores higher overall (69/100 vs 49/100), backed by strong 34.2% margins and 251.0% revenue growth. PFE offers better value entry with a 28.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Sandisk Corp
TECHNOLOGY · COMPUTER HARDWARE · USA
Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?